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Abstract
Background: Metabolic Syndrome, or Syndrome X, is characterized by a set of metabolic and lipid
imbalances that greatly increases the risk of developing diabetes and cardiovascular disease. The syndrome
is highly prevalent in the United States and worldwide, and treatments are in high demand. ProAlgaZyme,
a novel and proprietary freshwater algae infusion in purified water, has been the subject of several animal
studies and has demonstrated low toxicity even with chronic administration at elevated doses. The
infusion has been used historically for the treatment of several inflammatory and immune disorders in
humans and is considered well-tolerated. Here, the infusion is evaluated for its effects on the
cardiovascular risk factors present in metabolic syndrome in a randomized double-blind placebo-
controlled study involving 60 overweight and obese persons, ages 25–60. All participants received four
daily oral doses (1 fl oz) of ProAlgaZyme (N = 22) or water placebo (N = 30) for a total of 10 weeks, and
were encouraged to maintain their normal levels of physical activity. Blood sampling and anthropometric
measurements were taken at the beginning of the study period and after 4, 8 and 10 weeks of treatment.
Eight participants did not complete the study.
Results: ProAlgaZyme brought about statistically significant (p < 0.001) reductions in the following:
weight, body fat, total cholesterol, LDL-cholesterol, triglycerides, C-reactive protein and fasting blood
glucose levels, accompanied by a significant (p < 0.001) increase in HDL-cholesterol levels over the 10-
week study period. The infusion was well-tolerated and no side effects were noted.
Conclusion: ProAlgaZyme (4 fl oz daily) consumption resulted in significant reductions in weight and
blood glucose levels, while significantly improving serum lipid profiles and reducing markers of
inflammation, thus improving cardiovascular risk factors in overweight and obese subjects over a course
of 10 weeks with an absence of adverse side effects.
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Background
Multiple risk factor syndrome or metabolic syndrome (i.e.
the coexistence of several risk factors for artherosclerosis,
including hyperglycemia, dyslipidemia and hypertension
in the same individual) is a growing medical problem in
industrialized countries [1,2], with obesity being the cen-
tral and causal component.
Obesity, which is defined as an excess deposition of fat in
body fat stores, is determined using the Body Mass Index
or BMI scale. It could also be determined by bioelectrical
impedance methods, which gives an estimate of the
amount of fat stores in the body. The distribution of these
fat stores (android or gynoid) is known to be an inde-
pendent risk factor in obesity-related diseases.
In the United States, over 60% of the adult population is
now overweight or obese [3] and 47 million people have
metabolic syndrome, which will soon overtake cigarette
smoking as the number one risk factor for heart disease
[4,5]. Obesity and its related complications were consid-
ered for a long time to be limited to industrialized devel-
oped countries. This is however no longer the case, with a
high incidence now in developing countries who have
undergone lifestyle changes which increase the incidence
of these diseases.
Obesity has been shown to contribute to high serum cho-
lesterol, low HDL cholesterol and hyperglycemia, all of
which increase the chances of cardiovascular disease
(CVD) [6-8]. Correlations between central obesity and
high blood pressure, high blood cholesterol, low levels of
high density lipoprotein cholesterol and high fasting
blood glucose levels have been shown for both sexes in
various racial and ethnic groups [6-10].
The complications of obesity are worsened by oxidative
stress (imbalance between pro-oxidants and antioxidants
in favor of pro-oxidants). Recent research has shown that
long-term caloric restriction promotes longevity and
chronic overeating and obesity results in a condition that
mimics the aging process, which explains the higher prev-
alence of inflammation and free radicals, and metabolic
and cardiovascular diseases in overweight individuals.
Obesity may induce systemic oxidative stress, and
increased oxidative stress in accumulated fat is one of the
underlying causes of dysregulation of adipocytokines and
development of metabolic syndrome [6].
The increased chance of CVD and type 2 diabetes requires
therapeutic consideration for the vast numbers of over-
weight/obese persons now at high risk for these diseases
[11]. The current International Diabetes Foundation rec-
ommendations for preventing or delaying the develop-
ment of diabetes include both primary and secondary
interventions. The former emphasizes lifestyle changes
such as calorie restriction and increased physical activity,
and the latter (for people at high risk for CVD) uses phar-
macological agents [12] that specifically target individual
components of metabolic syndrome [12-17]. When used
by obese patients in combination with dietary regimes or
alone, these agents can produce some weight loss and
some prevention or reversal of accompanying complica-
tions. The role of pharmacotherapy, however, has been
compromised by safety issues leading to the withdrawal
of some medications from the market [18,19] or from
advanced stages of clinical testing. Furthermore, agents
that can address the underlying issues behind many of the
complications associated with metabolic syndrome have
yet to be developed.
This study investigated the effects of ProAlgaZyme algae
infusion ("PAZ") vs. placebo on indicators of cardiovascu-
lar health by assessing markers of inflammation and oxi-
dative stress, blood sugar, weight and blood lipids in
overweight and obese people. ProAlgaZyme (PAZ) is a
freshwater algae infusion that has been consumed as a liq-
uid dietary supplement for over 3 decades. PAZ was first
marketed as LebenszeitTM, meaning "Lifetime" in Ger-
man, in the 1980's by Ponce de Leon Medical Develop-
ment Corp. in the U.S., in reference to the legendary
fountain of youth. The product became known as
ProAlgaZyme or "PAZ" in 2003. The infusion is an aque-
ous fermentation product of a proprietary blend of fresh-
water organisms including green algae discovered over 30
years ago within a natural source, and has since been cul-
tivated under controlled conditions. ProAlgaZyme oral
liquid dietary supplement, the filtrate of the fermentation
process, typically has less than 100 ppm total dissolved
solids consisting of approximately 90% salts (free of
heavy metals at a detection limit of <0.1 ppm) and a
unique blend of organic constituents currently undergo-
ing full characterization.
Anecdotal reports in the U.S. of improvements in symp-
toms of inflammatory and metabolic conditions after PAZ
consumption led to our interest in evaluating PAZ's
potential to positively affect factors associated with meta-
bolic syndrome and cardiovascular health. Particularly
relevant to this study were anecdotal reports of improve-
ments in high sensitivity C-reactive protein, blood sugar
metabolism and body weight, and increases in energy.
Patients with metabolic syndrome were specially suited as
subjects in this study, as this diagnosis includes both met-
abolic and inflammatory components. The human clini-
cal study results are reported here.
Objectives of study
The main objective of the study was to establish the role
of ProAlgaZyme algae infusion (PAZ) vs. placebo to con-Lipids in Health and Disease 2007, 6:20 http://www.lipidworld.com/content/6/1/20
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trol inflammation and promote cardiovascular benefits in
overweight and obese people. Specific objectives were to
determine the effects of ProAlgaZyme vs. placebo on body
weight, BMI, blood lipids, fasting blood glucose levels
and markers of inflammation over a 10-week period.
Results
ProAlgaZyme had a significant effect on the various
parameters studied in metabolic syndrome patients over a
10 week period (Table 1). The raw data at 4, 8 and 10
weeks are in additional file 1: MetSyn_Data.xls.
A total of 52 overweight or obese participants aged 25 to
60 years completed the study (87%). Eight patients
dropped out of the study; three gave as a reason difficulty
in maintaining the dosing schedule, 3 others did not give
any reason, while 2 of them moved out of town. While no
side effects were reported in either the dropouts or in
those completing the trial, it is possible that unreported
reactions to the ProAlgaZyme treatment led to the deci-
sion in this subgroup to stop participation. Mitigating
against this possibility are results from a separate trial
(submitted for publication), in which 20 HIV+ individu-
als received 20 ounces per day (5 times the dose used in
this study) for a 12-week period, with no side effects
observed or reported.
Weight, BMI and body fat
After 10 weeks, participants receiving ProAlgaZyme had
significantly (p < 0.001) greater reductions in body weight
and consequently body mass index (BMI) compared to
placebo (Figure 1). This reduction was paralleled by a sig-
nificant decrease in the percentage of body fat over this
period in the treatment group vs. placebo (Table 1).
Blood pressure
After 8 weeks of treatment, PAZ significantly (p < 0.01 and
p < 0.001) reduced the systolic and diastolic blood pres-
sure of participants, respectively, compared to placebo
(Table 1)
Insulin and fasting blood glucose levels
Mean fasting blood glucose levels in metabolic syndrome
patients were significantly (p < 0.001) lowered in the PAZ
Table 1: The effect of ProAlgaZyme on various parameters related to metabolic syndrome. Bolded values represent mean ∆ after 10* 
weeks of treatment ± (1.96*SEM) for a 95% confidence level. Values in parentheses are mean starting values (at T = 0) ± (1.96*SEM). 
Significance indicates comparison of changes after 10* weeks of treatment with PAZ to placebo. A negative value indicates a decrease, while a 
positive value indicates an increase over the test period. *Values for RBC sedimentation, triglycerides, LDL-C and blood pressure are after 8 
weeks of treatment. NS = Not significant.
Parameters ∆ ProAlgaZyme (T = 0) ∆ Placebo (T = 0) Significance
Weight (kg) -4.18 ± 0.76
(86.70 ± 2.31)
-1.20 ± 0.29
(86.34 ± 2.61)
P < 0.001
BMI (kg/m2) -1.51 ± 0.28
(31.13 ± 0.62)
-0.20 ± 0.11
(31.95 ± 0.63)
P < 0.001
Body fat (%) -2.46 ± 3.51
(40.14 ± 0.79)
-0.30 ± 0.17
(41.88 ± 1.11)
P < 0.001
Blood pressure (Sys8, mm Hg) -10.32 ± 2.69
(152.23 ± 4.41)
-1.36 ± 2.18
(158.21 ± 4.39)
P < 0.01
Blood pressure (Dias8, mm Hg) -7.27 ± 2.50
(68.73 ± 2.58)
-2.32 ± 1.84
(72.82 ± 2.69)
P < 0.001
Insulin (uIU/mL) 1.28 ± 2.34
(23.48 ± 2.23)
-1.01 ± 1.57
(23.02 ± 3.18)
NS
Fasting blood glucose (mg/dL) -18.50 ± 5.56
(98.72 ± 5.65)
-0.58 ± 2.11
(98.41 ± 3.41)
P < 0.001
Total cholesterol (mg/dL) -64.84 ± 9.68
(201.94 ± 3.92)
-5.45 ± 2.51
(204.17 ± 3.87)
P < 0.001
HDL cholesterol (mg/dL) 15.37 ± 3.04
(37.02 ± 1.07)
-2.98 ± 1.53
(38.76 ± 1.44)
P < 0.001
LDL cholesterol8 (mg/dL) -40.63 ± 9.58
(131.32 ± 3.73)
-0.69 ± 2.79
(131.45 ± 4.15)
P < 0.001
Triglycerides8 (mg/dL) -18.77 ± 6.18
(167.95 ± 7.35)
-1.96 ± 4.52
(166.67 ± 4.64)
P < 0.001
RBC sed. rate8 (mm/h) -3.05 ± 0.78
(14.23 ± 0.58)
-0.25 ± 0.65
(14.36 ± 0.68)
P < 0.001
C-reactive protein (mg/L) -6.20 ± 0.92
(10.83 ± 0.51)
-0.83 ± 0.49
(11.41 ± 0.67)
P < 0.001
Interleukin-6 (pg/mL) -3.62 ± 1.03
(14.40 ± 2.01)
-0.03 ± 0.26
(12.65 ± 1.20)
P < 0.001
TNF-a (pg/mL) -0.65 ± 0.66
(11.22 ± 1.14)
-0.08 ± 0.44
(10.95 ± 0.84)
P < 0.05Lipids in Health and Disease 2007, 6:20 http://www.lipidworld.com/content/6/1/20
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group compared to placebo (Table 1). Although modest
increases in the circulating levels of insulin were observed
in the treatment group, these were not significant.
Blood lipids: total cholesterol, LDL-cholesterol, HDL-
cholesterol and triglycerides
PAZ brought about significant changes in all lipid param-
eters measured. In the treatment group, significant (p <
0.001) reductions were observed in circulating total cho-
lesterol (Figure 2), LDL-C and triglycerides over the 10-
week test period (Table 1). These changes were accompa-
nied by a significant (p < 0.001) increase in HDL-choles-
terol (Figure 3) while a decrease was observed in the
placebo group. Final values for LDL-C and triglycerides
were determined at T = 8 weeks; others parameters were at
T = 10 weeks.
Red blood cell sedimentation, C-reactive protein, 
interleukin-6, TNF-a
There were significantly greater decreases (p < 0.001)
compared to placebo in RBC sedimentation rate and con-
centrations of CRP (Figure 4) and IL-6 in test subjects after
10 weeks. Levels of TNF-alpha were less significantly (p <
0.05) altered.
Time course of effects
Individual patient values, means and calculations of per-
centage change from baseline for each parameter are avail-
able in additional file 1: MetSyn_Data.xls. Exemplary data
for changes as a function of time are shown graphically for
body weight, total cholesterol, HDL-C, and CRP in Figures
1, 2, 3, 4, respectively. Figure 1 shows that the rate of
change for body weight was greater than for the other
parameters, especially CRP. This raises the possibility that
the change in body weight is a primary effect and some or
all of the other changes may be secondary effects.
Discussion
In this study, we evaluated the effects of ProAlgaZyme
algae infusion (PAZ) on indicators of metabolic syn-
drome and subsequent risk factors for cardiovascular dis-
ease. The results obtained showed that PAZ is efficient in
improving multiple markers of metabolic syndrome
including weight, blood lipids, fasting blood glucose and
markers of inflammation, and may have a significant
effect on cardiovascular health. The infusion is effective in
reducing body weight in obese patients, with an average
weight loss of 4.2 kg (9 lbs.) over 10 weeks. This reduction
seems to be caused by the decrease in percentage of body
fat observed throughout the study in the PAZ group, with
an average loss of 2.6% body fat. Accumulation of body
fat is tightly linked to non-insulin dependent diabetes
mellitus (NIDDM). In this study, results also showed a
hypoglycemic effect of PAZ, with an average reduction in
fasting blood glucose of nearly 19% or 18.50 mg/dL. It
would be interesting to investigate whether this effect
could also be observed in people living with diabetes mel-
litus. Several hypotheses can be made in order to explain
the mechanism of the weight/fat loss and blood glucose
lowering effect. It should be noted that changes in blood
insulin were not significant. It is possible that PAZ may
contain some molecule(s) able to act on basal metabolic
The effect of ProAlgaZyme vs. placebo on total cholesterol  (mg/dL) Figure 2
The effect of ProAlgaZyme vs. placebo on total cho-
lesterol (mg/dL). Values are mean change at 4, 8 and 10 
weeks compared to baseline within 95% confidence limits (+/
- 1.96*(standard error of the mean)).
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The effect of ProAlgaZyme vs. placebo on body weight (kg) Figure 1
The effect of ProAlgaZyme vs. placebo on body 
weight (kg). Values are mean change at 4, 8 and 10 weeks 
compared to baseline within 95% confidence limits (+/- 
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rate (BMR), thus increasing energy expenditure and lead-
ing to consumption of excess fat stores. This hypothesis
could be assessed in a further study using calorimetry.
Appetite reducers in some cases could be linked to
reduced energy intake; however, it is unlikely to be the
case with the use of PAZ, since most participants reported
an increased rather than reduced appetite. The reduction
in inflammation induced by PAZ, as evidenced by
strongly decreased levels of C-reactive protein (mean
change -6.20 mg/L; -57%), should be considered here, as
it may be responsible for improving blood sugar profiles
through a reversal of the autoimmune component of
insulin resistance. With regard to lipid profile, strong
hypolipidemic effects of PAZ in the test group over a 10-
week period suggest its potential protection against cardi-
ovascular diseases through a reduction in total cholesterol
(mean -64.8 mg/dL; -32%), LDL-cholesterol (mean -40.6
mg/dL; -30%) and triglycerides (mean -18.8 mg/dL; -
11%), and an increase in HDL-cholesterol (mean 15.4
mg/dL; +42%). 1 out of 2 test subjects (n = 11) observed
an increase of ≥15 mg/dL in HDL-cholesterol over 10
weeks, and nearly a third (n = 7) saw an increase of 20 mg/
dL or more. All subjects taking ProAlgaZyme (vs. only
11% of subjects on placebo) saw an increase of ≥1 mg/dL
in HDL-C. An increase in HDL-cholesterol alone has been
shown to impart possible health benefits in overweight
and obese people and reduce the risk for cardiovascular
disease [20,21]. This increase in HDL-C coupled with a
decrease in the concentrations of LDL-C and triglycerides
could lead to a lowering of atherogenicity and therefore a
significant reduction in the potential incidence of coro-
nary heart disease [22]. Ten weeks of treatment with
ProAlgaZyme brought about a mean reduction in total
cholesterol of over 60 mg/dL, while only a 23.2 mg/dL
(0.6 mmol/L) reduction of serum cholesterol has been
shown to correlate with a 54% reduction of risk [23].
Additionally, half of test subjects observed a decrease in
LDL-C of at least 36 mg/dL. PAZ may achieve these effects
through interaction with enzymes involved in cholesterol
biosynthesis, by catalysis of LDL-cholesterol conversion
into bile salts, or by other mechanisms. Since a recruit-
ment criterion in the study was hyperlipidemia, these
results show clearly that PAZ could be used successfully
for the relief of dyslipidemia. This improvement in lipid
profile, coupled with a decrease in inflammatory markers,
could also assure a protection against lipid plaque
buildup and rupture in artery walls, and therefore against
cardiovascular disease and hypertension, as suggested in
the study by a decrease in blood pressures in PAZ patients.
Yet, we cannot exclude the presence of hypotensive mole-
cules in the infusion. Reductions in C-reactive protein,
RBC sedimentation rate and Interleukin-6 (IL-6) were sig-
nificantly greater in the PAZ group compared to placebo,
suggesting that PAZ also has a preventive effect on the pro-
inflammatory state generally linked to metabolic syn-
drome, and may be useful for the treatment of other
inflammatory disorders. 100% of test subjects (n = 22)
observed a 20% or more reduction in CRP (≥2.0 mg/L),
and half of these (n = 11) experienced a reduction of 55%
or more (≥6.0 mg/L). Collectively, these results support
the use of PAZ for weight loss and metabolic and lipid
imbalances, and warrant further investigation of the
potential effects of ProAlgaZyme on cardiovascular
health.
The effect of ProAlgaZyme vs. placebo on C-reactive protein  (mg/L) Figure 4
The effect of ProAlgaZyme vs. placebo on C-reactive 
protein (mg/L). Values are mean change at 4, 8 and 10 
weeks compared to baseline within 95% confidence limits (+/
- 1.96*(standard error of the mean)).
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The effect of ProAlgaZyme vs. placebo on HDL-cho-
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weeks compared to baseline within 95% confidence limits (+/
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Conclusion
ProAlgaZyme (PAZ) oral algae infusion demonstrated
multiple beneficial effects on the various aspects of meta-
bolic syndrome and may significantly promote cardiovas-
cular health in these subjects. ProAlgaZyme was able to
reduce body weight and BMI in overweight and obese per-
sons, and trigger an improvement in lipid profile charac-
terized by a decrease of blood total cholesterol, LDL-
cholesterol and triglycerides, coupled with an increase in
HDL-cholesterol. In addition, the infusion reduced fast-
ing blood glucose and brought about a diminution of
markers of inflammation. The infusion was well-tolerated
and no side effects were noted in the study. The changes
obtained after 10 weeks were significant (p < 0.05 or bet-
ter). These new findings warrant further exploration into
the active components in ProAlgaZyme and its potential
newly discovered metabolic and cardiovascular health
benefits.
Methods
Recruitment of participants for study
Recruitment of participants for the study was done from
the Laboratory of Nutrition and Nutritional Biochemistry
(LNNB) database, as well as by radio and poster adverts in
the Yaoundé area and at the University of Yaoundé I
Teaching Hospital. The recruitment adverts specifically
targeted participants with relatively high total and LDL-
cholesterol, as well as those with higher than normal fast-
ing blood glucose levels. This was achieved through an
initial free screening program organized by the LNNB. A
physician examined participants to ascertain their inclu-
sion into the study. Metabolic syndrome was diagnosed
using the American Heart Association criteria for the dis-
ease, which is described as a combination of the following
symptoms:
• Abdominal obesity (excessive fat tissue in and around
the abdomen)
• Atherogenic dyslipidemia (blood fat disorders – high
triglycerides, low HDL cholesterol and high LDL choles-
terol – that foster plaque buildups in artery walls)
• Elevated blood pressure
• Insulin resistance or glucose intolerance (the body can't
properly use insulin or blood sugar)
• Pro-thrombotic state (e.g., high fibrinogen or plasmino-
gen activator inhibitor-1 in the blood)
• Pro-inflammatory state (e.g., elevatedC-reactive protein
in the blood)
Subject selection
Inclusion Criteria
Participants were male or female, ages 25–60, and gave
their written informed consent. In addition, participants
met at least 3 of the following criteria:
• BMI ≥ 30 kg/m2
• HDL Cholesterol of < 40
• Triglycerides > 150 mg/dl
• Fasting blood glucose > 100 mg/dl
• Blood pressure > 130/85 mm Hg
• Total Cholesterol of > 200 mg/dl
• LDL Cholesterol of > 160 mg/dl
• Interleukin 6 (IL-6) > 5 pg/mL
And were excluded if they:
• Were morbidly obese: BMI > 40 kg/m2
• Were taking any cholesterol-lowering medications 30
days prior to the start of enrollment and during the course
of the study.
• Had been enrolled in another clinical study in the past
6 months.
• Were pregnant, actively infected, on medication that
interfered with healing (for example, steroids), were
inflicted with systemic disease such as AIDS, HIV, active
hepatitis or active malignancy (clinical signs within the
past 5 years), or suffered from diabetes mellitus requiring
daily insulin management.
Suitable participants were divided into two groups (Table
2). A total of 60 overweight or obese participants, ages
between 25 and 60 years, were selected from a group
responding to radio and poster adverts. The study was
conducted in a double-blind fashion, and patients were
randomly assigned to a treatment. The two groups were
studied in parallel for a total of 10 weeks.
The BMI of participants ranged from 28.3 to 38.1, and
their weights ranged from 74.3 to 107.6 kg. After physical
examination, which included measurement of blood
pressure, participants with unusually elevated fasting
blood glucose levels, pregnant or lactating, as well as
those on any form of weight, cholesterol, or inflamma-
tion-reducing medication were excluded from the study.Lipids in Health and Disease 2007, 6:20 http://www.lipidworld.com/content/6/1/20
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Also excluded were participants involved in intense exer-
cise programs, those who had medical conditions known
to affect serum lipids or those who had a history of drug
or alcohol abuse.
The study was approved by the University of Yaoundé
Internal Review Board. The purpose, nature and potential
risks of the study were explained to all participants, who
gave their written informed consent before participation.
The study was conducted in accordance with the Helsinki
Declaration (1983 version).
Study material and dosing regimen
ProAlgaZyme freshwater algae infusion (PAZ) and water
placebo were obtained from Health Enhancement Prod-
ucts, Inc., Scottsdale, Arizona, USA. Materials had identi-
cal taste and appearance, and were packaged and labeled
identically.
Baseline values were established in the first week, and
ProAlgaZyme or placebo was administered orally for a
total of 10 weeks. Each participant received 4 oz. of PAZ
or placebo per day, divided into 4 equal doses of 1 oz.
taken at breakfast, lunch, dinner and bedtime.
Sample collection, parameters to be measured and 
timelines
At each of four time points, the testing protocol followed
the order: blood sample collection, anthropometric meas-
urements, administration of questionnaires. Time points
were as follows: at the start (T = 0), as well as at 4, 8 and
10 weeks, i.e. T = 4, T = 8 and T = 10. The various anthro-
pometric and biochemical parameters were analyzed
using different methods and analytical kits as outlined
below.
Anthropometry
Body weight and percent body fat were determined in
overnight-fasted participants using a Tanita™ scale. Height
was measured with a stadiometer to the nearest 0.5 cm,
and BMI was expressed as weight (kilograms) per height
(meters) squared.
Blood pressure
Blood pressure was measured on three different occasions
using a mercury sphygmomanometer. After measuring
blood pressure on day 1, a second measurement was
obtained about a week later, and a third measurement 1
to 3 days later. On each occasion at least 2 readings were
taken and the mean value recorded. An appropriate adult
cuff was applied 2 to 3 cm above the antecubital fossa of
the right arm. Blood pressure was measured to the nearest
2 mm Hg, reading the calibration below the meniscus
with the subject in the sitting position. Systolic and
diastolic blood pressures were read at the 1st and 5th
Korotkoff phases, respectively. The mean of the 3 blood
pressure values obtained from the 3 visits was recorded as
the subject's true blood pressure. Hypertension was
defined as systolic and diastolic blood pressures equal to
or more than 135 mm Hg and 85 mm Hg, respectively
[24].
Sample collection and treatment
Fasting blood (5 ml) was collected by venous puncture
from subjects after an overnight fast at each of the time
points, and distributed into heparinized tubes. After cen-
trifugation at 3000 g for 10 minutes at 4°C plasma was
stored in 0.5 ml aliquots at -80°C, and analyzed within 2
weeks.
Biochemical analyses of plasma
Plasma total cholesterol was measured by the cholesterol
oxidase method [25] while plasma triglyceride was deter-
mined as described by Bucolo and David [26]. HDL cho-
lesterol was determined using a heparin manganese
precipitation of Apo B-containing lipoproteins [27]. LDL
cholesterol was calculated using the Friedewald formula
[28]. Blood glucose was determined using the methods of
Trinder [29]. CRP was determined using a turbidimetric
method [30].
Biochemical and physiological parameters
Parameters relating to metabolic syndrome were meas-
ured at four time points (T = 0, 4, 8 & 10 wk) (Table 3) in
treatment and placebo group subjects.
Statistical analyses
Statistical Package for the Social Sciences (SPSS) [31] soft-
ware was used for all statistical analysis. The data were pre-
sented as means ± (1.96*SEM) for a 95% confidence level.
The statistical difference between samples was assessed by
a student's t-test for normal distribution or the Mann-
Whitney test for non-normal distribution, after ANOVA
testing of all the groups showed that significant difference
existed. Paired Student's t-test was carried out on the start
and end values of the groups.
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